March 2026
Serotonin
What March 2026's 15 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 15 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research in March 2026 found that serotonergic psychedelics like psilocybin promote neuroplasticity through 5-HT2A receptor signaling and BDNF-TrkB pathways, with effects on synaptic structure, brain network propagation, and affective bias. Results are consistent across cellular, rodent, and human studies, but most evidence comes from preclinical models and small clinical samples, with limited data on long-term durability and clinical translation.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Reshaping human neurons. 2026 | in vitro | Supports | Psilocin increased structural complexity and synaptic connections in human neurons. | |
| Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders 2026 | review | Supports | Classical serotonergic psychedelics produce rapid and durable mood improvements, with mechanisms involving 5-HT2A receptors, BDNF-TrkB signaling, and network reorganization. | |
| Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. 2026 | in vitro | Supports | Psilocin increased BDNF, neuronal complexity, synaptic proteins, and network activity via 5-HT2A receptors. | |
| Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors 2026 | observational (fMRI) | Supports | Psilocybin modulated global brain activity propagation, linked to 5-HT2A receptor distribution. | |
| Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies 2026 | review | Supports | Psychedelics challenge traditional monoamine models, highlighting glutamatergic signaling and synaptic plasticity. | |
| Integrated 5-HT 2A –TrkB and G protein signaling in serotonergic psychedelic responses 2026 | in vitro | Supports | Serotonergic psychedelics induced dendritogenesis and synaptogenesis via 5-HT2A and TrkB signaling, with ligand-specific differences. | |
| Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil. 2026 | cross-sectional survey | 28 | Mixed | Athletes had low awareness but positive attitudes toward psychedelic therapies; 64% lacked mental health support. |
| Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials. 2026 | animal study | Mixed | Chronic fluoxetine reduced DOI-induced head-twitch, but acute fluoxetine attenuated psilocybin efficacy, suggesting compound-specific SSRI interactions. | |
| Serotonergic modulation of excitatory synapse development and plasticity 2026 | review | Supports | Serotonin modulates excitatory synapse development and plasticity through multiple receptor subtypes. | |
| Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response 2026 | animal study | Supports | Combining psilocybin with a PDE9 inhibitor reduced head-twitch while maintaining antidepressant-like effects, dissociating psychedelic and therapeutic responses. | |
| VeronicaMaki-Marttunen/Psilocybin-shapes-propagation-of-brain-activity: Mäki-Marttunen-Psilocybin-shapes-propagation-of-brain-activity 2026 | code/software | Unclear | Code accompanying the fMRI study on psilocybin and brain activity propagation. | |
| A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats 2026 | animal study | Mixed | Repeated low-dose MDMA caused transient anxiety-like behavior and reduced serotonin in nucleus accumbens, but no anhedonia. | |
| Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin 2026 | animal study | Supports | Psilocin modulated affective biases via 5-HT1A and 5-HT2A receptors, with sustained effects 24 hours after infusion. | |
| Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs 2026 | chemical synthesis | Unclear | Only psilocin showed binding at serotonin receptor subtypes among psilocybin metabolites tested. | |
| Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors 2026 | animal study | Supports | Psychedelic-induced plasticity occurred in cortical neurons lacking postsynaptic 5-HT2A receptors, via presynaptic receptors. |
Psilocin increased structural complexity and synaptic connections in human neurons.
in vitro
Classical serotonergic psychedelics produce rapid and durable mood improvements, with mechanisms involving 5-HT2A receptors, BDNF-TrkB signaling, and network reorganization.
review
Psilocin increased BDNF, neuronal complexity, synaptic proteins, and network activity via 5-HT2A receptors.
in vitro
Psilocybin modulated global brain activity propagation, linked to 5-HT2A receptor distribution.
observational (fMRI)
Psychedelics challenge traditional monoamine models, highlighting glutamatergic signaling and synaptic plasticity.
review
Serotonergic psychedelics induced dendritogenesis and synaptogenesis via 5-HT2A and TrkB signaling, with ligand-specific differences.
in vitro
Athletes had low awareness but positive attitudes toward psychedelic therapies; 64% lacked mental health support.
cross-sectional survey Sample size: 28
Chronic fluoxetine reduced DOI-induced head-twitch, but acute fluoxetine attenuated psilocybin efficacy, suggesting compound-specific SSRI interactions.
animal study
Serotonin modulates excitatory synapse development and plasticity through multiple receptor subtypes.
review
Combining psilocybin with a PDE9 inhibitor reduced head-twitch while maintaining antidepressant-like effects, dissociating psychedelic and therapeutic responses.
animal study
Code accompanying the fMRI study on psilocybin and brain activity propagation.
code/software
Repeated low-dose MDMA caused transient anxiety-like behavior and reduced serotonin in nucleus accumbens, but no anhedonia.
animal study
Psilocin modulated affective biases via 5-HT1A and 5-HT2A receptors, with sustained effects 24 hours after infusion.
animal study
Only psilocin showed binding at serotonin receptor subtypes among psilocybin metabolites tested.
chemical synthesis
Psychedelic-induced plasticity occurred in cortical neurons lacking postsynaptic 5-HT2A receptors, via presynaptic receptors.
animal study
Points of agreement
- Serotonergic psychedelics promote neuroplasticity through 5-HT2A receptor activation and BDNF-TrkB signaling.
- Psilocybin and psilocin enhance synaptic structure, complexity, and network activity in human neurons and animal models.
- Therapeutic effects involve modulation of brain network dynamics and affective biases.
Conflicts
- One study (27898) found plasticity in neurons lacking postsynaptic 5-HT2A receptors, while others emphasize postsynaptic 5-HT2A necessity.
- Acute psychedelic effects may not be required for antidepressant response (24989), but other studies link mystical experiences to outcomes (28040).
- SSRI interactions with psychedelics vary by compound and duration (27926).
Gaps
- Durability of neuroplastic changes and clinical outcomes beyond acute effects.
- Large-scale, well-blinded RCTs in clinical populations.
- Mechanisms in humans beyond fMRI and in vitro models.
- Effects in diverse populations (e.g., athletes, elderly, comorbid conditions).
- Dose-response relationships and optimal regimens.